Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Study Phase:
Other
Recruitment Status:
Not Yet Recruiting
Study Drug(s):
Azithromycin
Number of Participants Being Recruited:
150
Single / Multi-Center:
Multi-Center
STUDY BACKGROUND INFORMATION:
It is now known that lung disease begins very early in some children with CF, even before breathing problems develop. Current treatments do not prevent lung damage from occurring and as many as 70% of 3 year olds with CF have lung damage such as bronchiectasis shown on a Chest CT scan. This study will look at whether treatment with azithromycin, a drug that has been found to help people with CF, can prevent the development of bronchiectasis.
ELIGIBILITY
Age:
3 Months -
FEV1:
- Percent Predicted
P. aeruginosa status:
Not applicable
B. cepacia status:
Not applicable
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
